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Introduction
 Endometrial cancer is the sixth most common cancer 
worldwide and third most common cancer in developed 
countries. In United States it is the most common cancer 
of genital tract. It is estimated that 47,100 new endometrial 
cancer occurred in 2012 with 8100 women dying from the 
disease (Jemal et al., 2011). Approximately 75% of cases 
DUHFRQÀQHGWRXWHUXVDQGPRVWSDWLHQWVZLWKHQGRPHWULDO
cancer have stage I disease. Socio economic factors are 
also important. African American race and low income 
QHLJKERUKRRGVGHFUHDVHGWKHFDQFHUVSHFLÀFVXUYLYDOE\
20% and 3% respectively at 5 years (Cheung, 2013). 
 Surgery is the primary treatment modality  and adjuvant 
therapy in stage I endometrial cancer is controversial. 
Patients with grade 1-2 tumors have low risk of recurrence 
but those with grade 3 disease have higher risk (Wright 
et al., 2012). Overall survival in stage IB (formerly IC) 
is 87% and 84% for patients with grade 1 and 2 tumors 
and drops to 66% in those with grade 3 disease (Fleming 
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Abstract
 Background: Most patients with endometrial cancer have stage I disease. Adjuvant therapy in stage IB 
(formerly IC) endometrial cancer is controversial, treatment options including observation or brachytherapy/
radiotherapy in grade 1-3 patients with or without chemotherapy. The purpose of this study was to assess 
the outcomes of our patients with stage IB endometrioid endometrial cancer. Materials and Methods: Sixty 
two patients with stage IB endometrial cancer and endometrioid histology were retrospectively evaluated. All 
patients were initially treated surgically by the same surgeon with comprehensive staging, i.e. total abdominal 
hysterectomy, bilateral salphingooopherectomy, bilateral pelvic and paraaortic lymph node dissection and 
omentectomy. Adjuvant radiotherapy was discussed with patients and utilized by those who accepted. Adjuvant 
chemotherapy was not given to any of the patients. Results: Median age was 62 (range, 42-95). Ninety percent 
of the patients had grade 1-2 disease. Thirteen patients (21%) received intra vaginal brachytherapy (IVBT) and 
one received whole pelvic radiotherapy (WPRT). Median follow-up time was 46 months (range, 9-77 months). 
Three patients experienced recurrence (4.8%), two of them died on follow-up and one was still alive at last visit. 
Two patients with recurrence had FIGO grade 2 tumors and one had a grade 3 tumor. Two patients (3.2%) 
died without evidence of recurrent disease. Relapse free survival at 5 years was 94.4% and overall survival was 
93.1%. Conclusions: Patients with stage IB disease in our study demonstrated relatively low recurrence rates 
DOWKRXJKWKHPDMRULW\RIWKHPUHFHLYHGQRDGMXYDQWWUHDWPHQW6XUJHU\DORQHPD\EHVXIÀFLHQWIRUPRVWSDWLHQWV
with this stage of endometrial cancer. 
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(2007). Radiotherapy reduces the risk of local recurrence 
EXWLWKDVQRVXUYLYDOEHQHÀW6FKROWHQHWDO7KLV
is to some extent because of the high salvage rate after 
vaginal relapse in a non-irradiated patient. Nearly one 
third of the patients with stage IB grade 3 cancer have 
GLVWDQWPHWDVWDVHVRQIROORZXSZKLFKMXVWLÀHVWKHXVH
of an effective adjuvant chemotherapy. However data 
on adjuvant chemotherapy in this patient population is 
limited, although it was shown to improve progression free 
survival in a subgroup analysis of the Nordic Society of 
Gynecological Oncology/European Organisation for the 
Research and Treatment of Cancer(NSOG/EORTC) trial 
(Hogberg et al., 2010). Ongoing trials including GOG 249 
and PORTEC 3 are investigating the role of chemotherapy 
in adjuvant setting. 1988 FIGO staging of endometrial 
cancer was revised in 2009. Formerly stage IC disease 
(>50% myometrial invasion, negative pelvic cytology, 
no cervical mucosal involvement) is now staged as IB. 
We herein aimed to analyze the treatment outcomes of 
our patients with stage IB uterine endometrioid cancer.
Samed Rahatli et al
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Materials and Methods
 Stage IB endometrial cancer patients with endometrioid 
histology treated in our institution from June 2006 until 
May 2012 were retrospectively evaluated. All patients 
were initially treated surgically by the same surgeon with 
comprehensive staging, i.e. total abdominal hysterectomy 
(TAH), bilateral salphingooopherectomy (BSO), bilateral 
pelvic and paraaortic lymph node dissection (BPPLND) 
and omentectomy. Demographic features, tumor 
characteristics, treatment regimens and patient outcomes 
in terms of disease free survival (DFS) and overall survival 
(OS) were analyzed. 
Statistical analysis
 Descriptive analysis was performed for demographic 
and clinical characteristics of the patients. Kaplan–Meier 
analysis was performed to examine OS or DFS. Disease 
IUHHVXUYLYDOZDVGHÀQHGDVWKHWLPHIURPSULPDU\VXUJHU\
until recurrence of tumor or death from any cause. Overall 
VXUYLYDOZDVGHÀQHGDVWKHLQWHUYDOIURPSULPDU\VXUJHU\
to the date of death or last follow-up. Statistical analysis 
was performed with SPSS software version 17.0 (SPSS 
,QF&KLFDJR,/DQGVWDWLVWLFDOVLJQLÀFDQFHZDVVHWDWS
less than 0.05.
Results 
 Sixty two women with stage IB endometrioid type 
HQGRPHWULDO FDQFHUZHUH LGHQWLÀHG 3DWLHQW DQG WXPRU
characteristics and treatment protocols are shown in Table 
1. Median age was 62 (range, 42-95). Forty patients (65%) 
had at least one comorbid disease including diabetes 
mellitus, hypertension, goiter or ischemic heart disease.
 None of the patients received adjuvant chemotherapy. 
Adjuvant brachytherapy is routinely offered to and 
discussed with patients with stage IB disease in our 
institution and performed in those who accept. Thirteen 
patients (21%) received intra vaginal brachytherapy 
(IVBT) and one received whole pelvic radiotherapy 
(WPRT). Age, body mass index, tumor size, histological 
grade, lymphovascular invasion rate, myometrial invasion 
depth and number of lymph nodes dissected were similar 
between the patients who received brachytherapy and 
those who did not.
 Median follow-up time was 46 months (range, 9-77 
months). Relapse free survival at 5 years was 94.4% and 
overall survival was 93.1%. Three patients experienced 
recurrence (4.8%), two of them died on follow-up and one 
was still alive at last visit. Two patients with recurrence 
had FIGO grade 2 tumors and one had grade 3 tumor. Two 
patients (3.2%) died without evidence of recurrent disease. 
Characteristics of the patients who had recurrence and/or 
died are shown in Table 2.
Discussion
The treatment of early stage endometrial cancer is 
not well established. 5-year OS is 92.4% for stage IA, 
87.3% for IB and 75.7% for IC disease (Abu-Rustum 
et al., 2011). Surgery is the mainstay of staging and 
treatment but chemotherapy and radiotherapy are also 
used in selected patients. Total laparoscopic hysterectomy 
or total abdominal hysterectomy may be preferred 
options (Wang  et al., 2013). Observation, whole pelvic 
radiotherapy, brachytherapy and chemotherapy are all 
treatment options recommended for stage IB disease in 
NCCN guidelines but which treatment for which particular 
patient is not clear. Adjuvant radiotherapy was previously 
shown to reduce local recurrence but no effect was found 
on overall survival in a number of randomized studies 
as well as a recent Cochrane meta- analysis (Kong et 
al., 2012; Setakornnukul et al., 2014). However these 
studies had limitations including no or low rate of pelvic/
paraaortic lymph node dissection (Creutzberg et al., 2000), 
combination of patients at different disease stages and 
non-uniform high risk criteria. In contrast, the surgical 
procedure was more extensive in our study. All our 
patients had TAH+BSO, omentectomy and both pelvic and 
paraaortic lymph node dissection with median 8 paraaortic 
and 30 pelvic lymph nodes removed. PPLND was optional 
or selective in most of the previous studies. PPLND has 
a real diagnostic value and assumed therapeutic value in 
the management of endometrial cancer. As high as 30% 
of the patients with apparently stage I disease was found 
to have lymph node metastases depending on the depth 
of myometrial invasion and tumor grade (Creasman et 
al., 1987). Therefore when PPLND is not performed, the 
groups of patients in clinical studies with apparently stage 
I disease might also harbor patients with occult lymph 
Table 1. Patient Characteristics
Patient characteristics No.  (%)
Age  62 (42-95)
BMI  31 (20-50)
Grade 1 23 (37.1)
 2 33 (53.2)
 3 5 (8)
Tumor size (cm)  3 (1-7)
Lymphovascular invasion + 21 (35.5)
 - 40 (64.5)
#of lymph nodes dissected (median)  37 (6-98)
Pelvic  30 (6-66)
Paraaortic  8 (0-32)
Whole pelvis radiotherapy  1 (1.6)
Intravaginal brachytherapy  13 (21)
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Table 2. Characteristics of the Patients Who Died or Relapsed on Follow-up
Patient Age Grade LVI Adjuvant treatment RFS Site of recurrence Outcome
1 85 2 + - - - Died without recurrence after 15 mos
2 72 2 + - - - Died without recurrence after  11 mos
3 54 2 + - 28.8 mos Paraaortic Recurrence was surgically excised. 
       Alive with no evidence of disease after 44 mos
4 55 3 - Intravaginal brachytherapy 38.3 mos Peritoneum Died with disease after 73 mos
5 53 2 - - 9 mos Vaginal cuff and inguinal Died with disease after 39 mos
      lymph nodes
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QRGHPHWDVWDVHVDQGVWDJH,,,GLVHDVHWKHUHRIDQGEHQHÀW
of additional treatment in this heterogeneous population 
PLJKWEHFRQÀQHGWRWKHVHKLJKHUVWDJHSDWLHQWV33/1'
might also have some therapeutic value and reduce the 
benefit of any further treatment. The same situation 
is also applicable for adjuvant chemotherapy. In the 
combined analysis of the NSGO/EORTC and MaNGO/
,/,$'(WULDOVVLJQLÀFDQWEHQHÀWRIFKHPRWKHUDS\ZDV
demonstrated in the NSGO/EORTC trial where LND 
was performed in less than 20% of the patients but not 
in the MaNGO trial where LND was performed in nearly 
half of the patients (Hogberg et al., 2010). Our study is 
retrospective, none of the patients received chemotherapy 
and 13 patients (21%) received radiotherapy (mostly 
brachytherapy). RT was offered to all patients with stage 
IB grade 2-3 diease but only 21% accepted. Low number 
of the patients and lack of pre-specified criteria for 
tailoring treatment preclude any comparison of outcomes 
between treatment modalities. Second, most of our 
patients had grade 1 or 2 disease .Only 6.5% of the patients 
had grade 3 disease. Nevertheless, given the low number 
of recurrences compared to the pertinent literature after 46 
months of follow up, we propose that not all patients with 
stage IB disease need treatment particularly if they have 
grade 1-2 disease and extensive lymph node dissection is 
performed. A recent retrospective study demonstrated 3 
year cumulative failure rate of 5.4% in patients with grade 
1-2 disease and 29% in those with grade 3 disease, most 
of the recurrences being distant and fatal (Long et al., 
2012). Therefore, grade seems to be the most important 
factor in making treatment decisions in stage IB disease. 
Lymphovascular invasion was also found to be associated 
with high recurrence rate (25%) among patients with stage 
IB-IIA endometrial cancer (Sukumaran et al., 2011).
In conclusion, patients with stage IB grade 1-2 disease 
in our study have relatively low recurrence rates although 
majority of them received no adjuvant treatment. All our 
patients had comprehensive staging surgery including 
systemic lymphadenectomy, which eliminated those 
patients with micrometastatic disease in lymph nodes or 
other sites (occult stage III patients) from the cohort and 
might have a role in the low recurrence rate obtained. 
Vaginal brachytherapy alone may be a treatment option 
given the encouraging effect on local recurrence and 
low morbidity rate (Nout et al.,2012). Patients with 
grade 3 disease were under represented in our cohort but 
particularly distant failure rates are high in the literature 
DQG V\VWHPLF WKHUDS\PLJKW EH MXVWLÀHG IRU WKHVH KLJK
risk patients. 
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